These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 27570091)
1. Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works. Inoue S; Okiyama N; Okune M; Shiraki N; Kessoku R; Fujimoto M J Dermatol; 2017 Jan; 44(1):84-87. PubMed ID: 27570091 [TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Tefferi A; Barbui T Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051 [TBL] [Abstract][Full Text] [Related]
3. Contemporary management of essential thrombocythemia in children. Randi ML; Bertozzi I; Putti MC Expert Rev Hematol; 2019 May; 12(5):367-373. PubMed ID: 30925843 [TBL] [Abstract][Full Text] [Related]
4. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. Tefferi A; Barbui T Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403 [TBL] [Abstract][Full Text] [Related]
5. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Tefferi A; Barbui T Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939 [TBL] [Abstract][Full Text] [Related]
13. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2 Saki N; Shirzad R; Rahim F; Saki Malehi A Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126 [TBL] [Abstract][Full Text] [Related]
14. Anagrelide and Mutational Status in Essential Thrombocythemia. Iurlo A; Cattaneo D; Orofino N; Bucelli C; Fabris S; Cortelezzi A BioDrugs; 2016 Jun; 30(3):219-23. PubMed ID: 27041108 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. Mela Osorio MJ; Ferrari L; Goette NP; Gutierrez MI; Glembotsky AC; Maldonado AC; Lev PR; Alvarez C; Korin L; Marta RF; Molinas FC; Heller PG Eur J Haematol; 2016 Apr; 96(4):435-42. PubMed ID: 26119186 [TBL] [Abstract][Full Text] [Related]
16. Two faces of ET: CALR and JAK2. Chao MP; Gotlib J Blood; 2014 Mar; 123(10):1438-40. PubMed ID: 24627549 [TBL] [Abstract][Full Text] [Related]
17. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987 [TBL] [Abstract][Full Text] [Related]
18. Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea. Dua V; Yadav SP; Kumar V; Saxena R; Sachdeva A Int J Hematol; 2012 Dec; 96(6):810-3. PubMed ID: 23054653 [TBL] [Abstract][Full Text] [Related]
19. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea. Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726 [TBL] [Abstract][Full Text] [Related]
20. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]